Ambit Wins Global Genes’ RARE-X Xcelerate RARE Open Science Data Challenge

Ambit Inc. proudly announces that it has been named a winner in the Xcelerate RARE Open Science Data Challenge, hosted by Global Genes’ RARE-X.  Our Data and Analytics team was recognized for its innovative computational approach in predicting disease diagnoses based on patient-reported data.


Ambit Partners with Datavant

Ambit Partners with Datavant to Drive Innovation in the Rare and Specialty Disease Markets

Ambit, a leading integrated biopharma solutions firm specializing in the rare and specialty disease markets, is pleased to announce a partnership with Datavant, the leader in helping organizations securely connect health data, to accelerate data-driven innovation for biopharma companies.

Dan McNamara joins Ambit

Ambit Welcomes Dan McNamara as EVP, Commercial and Patient Strategy

With an extensive background in the pharmaceutical industry and a passion for revolutionizing patient care, McNamara is poised to lead Ambit’s charge in elevating patient strategy to unprecedented heights within the rare and specialty disease sectors.

Ambit Redefines Biopharma Solutions with Dynamic New Branding Approach

New branding emphasizes dedication and commitment to deliver best-in-class solutions for biopharma

Ambit one year anniversary

Reflecting on One Year of Impact: Celebrating and Building on our Achievements

With the goal of helping our clients solve their most complex challenges in biopharma, our approach has been to develop novel solutions by combining with advanced analytics, commercial, medical, and digital strategy, and omnichannel execution.

Ambit Inc. to Present Novel Projection Methodology for Rare Developmental and Epileptic Encephalopathies (DEEs) at the 2022 Child Neurology Society Annual Meeting

Ambit to showcase its prevalence projection approach, co-developed with Praxis, for rare developmental and epileptic encephalopathies (DEEs) as a Platform Presentation at this year’s annual Child Neurology Society meeting.

Ambit Hires Jonathan Woodring as Chief Innovation Officer

Former executive to drive data and analytics product strategy, development, and commercialization.

A new look for Ambit

Our brand may be changing, but our focus remains the same. We are committed to developing novel solutions that enable our biopharma clients to adapt to the challenges and opportunities in the rare and specialty disease markets.